FrancophonIA/ELRC3.0 huggingface dataset:
English: Renal impairment: The systemic availability and half-life of nateglinide in diabetic patients with mild, moderate (creatinine clearance 31-50 ml/min) and severe (creatinine clearance 15-30 ml/min) renal impairment (not undergoing dialysis) did not differ to a clinically significant degree from those in healthy subjects.
Maltese: Id-disponibilità sistemika u l-half-life ta' nateglinide f'pazjenti b'indeboliment renali ħafif għal moderat (tneħħija tal-krejatinina 31-50 ml/min) u severa (tneħħija tal-krejatinina 1530 ml/min) (mhux fuq dijaliżi) moderat ma kienx differenti b'mod klinikament sinifikanti minn dawk f'pazjenti b'saħħithom.
English: Consistent with its short elimination half-life, there is no apparent accumulation of nateglinide upon multiple dosing with up to 240 mg three times daily.
Maltese: B'mod konsistenti mal-half-life tat-tneħħija qasir li għandu, ma jidhirx li jkun hemm akkumulazzjoni ta' nateglinide meta jingħataw ħafna dożi sa 240 mg tlett darbiet kuljum.
English: In an interaction trial with sulfinpyrazone, a CYP2C9 inhibitor, a modest increase in nateglinide AUC (~28%) was observed in healthy volunteers, with no changes in the mean Cmax and elimination half-life.
Maltese: Fi studju ta' interazzjoni ma' sulfinpyrazone, impeditur ta' CYP2C9, ġiet osservata żieda żgħira (28 %) f'voluntiera b'saħħithom fl-AUC ta' nateglinide, bl-ebda tibdil fil-medja tas-Cmax u l-half-life ta' l-eliminazzjoni.
English: Inhibitors of drug metabolism such as fluconazole (used to treat fungal infection), gemfibrozil (used to treat dyslipidaemia) or sulfinpyrazone (used to treat chronic gout).
Maltese: - Impedituri tal-metaboliżmu tal-mediċini bħal fluconazole (użati biex jikkuraw infezzjonijiet tal moffa), gemfibrizol (użat fil-kura ta' diżlipidemija) jew sulfinpyrazone (użat fil-kura tal-gotta
English: Data available from both in vitro and in vivo experiments indicate that nateglinide is predominantly metabolised by CYP2C9 with involvement of CYP3A4 to a smaller extent.
Maltese: Stħarriġ minn esperimenti in vitro u in vivo jindikaw illi nateglinide huwa metabolizzat l-aktar minn CYP2C9 b'involviment minuri minn CYP3A4.
English: The efficacy of nateglinide in combination with metformin has been compared to the combination of gliclazide plus metformin in a 6-month randomised, double-blind trial in 262 patients using a superiority design.
Maltese: L-effikaċja ta' nateglinide ma' metformin kienet imqabbla mat-taħlita ta' gliclazide ma' metformin fi prova randomised ta' 6 xhur double blind f'262 pazjent b'disinn ta' superjorità.
English: Nateglinide-induced insulin secretion by pancreatic beta cells is glucose-sensitive, such that less insulin is secreted as glucose levels fall.
Maltese: Is-sekrezzjoni ta' insulina mqanqla b'nateglinide miċ-ċelluli beta tal-frixa hija sensittiva għal glucose, b'mod li tiġi mgħamula inqas insulina malli jaqaw il-livelli ta' glucose.
English: Corticosteroids such as prednisone and cortisone (used to treat inflammatory disorders).
Maltese: - Kortikosterojdi bħal prednisone u cortisone (użati biex jikkuraw problemi nfjammatorji).
English: NAME OF THE MEDICINAL PRODUCT Trazec 60 mg tablets
Maltese: Trazec 60 mg pilloli
English: A more prolonged effect and possibly a risk of hypoglycaemia cannot be excluded in patients when nateglinide is co-administered with CYP2C9 inhibitors.
Maltese: Effett imtawwal u possibilment riskju ta' ipogliċemija ma jistgħux jiġu esklużi meta nateglinide jingħata ma' impedituri CYP2C9.
English: Post-marketing data revealed very rare cases of erythema multiforme.
Maltese: Tagħrif ta' wara t-tqegħid fis-suq wera każijiet rari ħafna ta' erythema multiforme.
English: In type 2 diabetic patients given Trazec over the dose range 60 to 240 mg before three meals per day for one week, nateglinide showed linear pharmacokinetics for both AUC and Cmax, and
Maltese: F'pazjenti dijabetiċi tip 2 mogħtija Trazec fuq firxa ta' dożi minn 60 sa 240 mg qabel tlett ikliet kuljum għall ġimgħa, nateglinide wera farmakokinetiċi linjari għal AUC u Cmax, u tmax li kien independenti mid-doża.
English: This depolarises the beta cell and leads to an opening of the calcium channels.
Maltese: Dan jiddepolarizza ċ-ċellula beta u jirriżulta fil-ftuħ tal-kanali ta' calcium.
English: Electrophysiological studies demonstrate that nateglinide has 45-300-fold selectivity for pancreatic beta cell versus cardiovascular K+ATP channels.
Maltese: Studji elettrofiżjiologiċi juri li nateglinide għandu selettività għaċ-ċelluli beta tal-frixa ta' 45300-il-darba iżjed mill-kanali kardjovaskolari K
English: There is a 49% decrease in Cmax of nateglinide in dialysis-dependent diabetic patients.
Maltese: Hemm tnaqqis ta' 49 % fis-Cmax ta' nateglinide f'pazjenti dijabetiċi li jiddependu mid-dijaliżi.
English: What Trazec looks like and contents of the pack Trazec 60 mg film-coated tablets are pink, round tablets with “NVR” marked on one side and “TS” on
Maltese: Id-Dehra ta' Trazec u l-kontenuti tal-pakkett Trazec 60 mg pilloli miksijin b'rita huma roża, tondi b'“NVR” immarkata fuq naħa u “TS” fuq l-oħra.
English: Symptoms of hypoglycaemia (unconfirmed by blood glucose levels) were observed in patients whose baseline HbA1c was close to the therapeutic target (HbA1C <7.5%).
Maltese: Sintomi ta' ipogliċemija (mhux ikkonfermati bil-livelli ta' glucose fid-demm) kienu osservati f'pazjenti li kellhom il-linja bażi ta' HbA1c viċin għall-livell terapewtiku mixtieq (HbA1C < 7.5 %).
English: The resulting calcium influx enhances insulin secretion.
Maltese: L-influss ta' calcium li jirriżulta jkabbar is-sekrezzjoni ta' insulina.
English: Most of the [14C] nateglinide is excreted in the urine (83%), with an additional 10% eliminated in the faeces.
Maltese: Il-parti l-kbira ta' [14C] nateglinide jitneħħa fl-awrina (83 %), b' 10 % oħra li jitneħħaew ma' l-ippurgar.
English: Patients with hepatic impairment
Maltese: Indeboliment epatiku:
English: Approximately 75% of the administered [14C] nateglinide is recovered in the urine within six hours post-dose.
Maltese: Madwar 75 % ta' [14C] nateglinide li jingħata jiġi rkuprat mill-awrina sa sitt siegħat wara t-teħid tad-doża.
English: The following agents may enhance the hypoglycaemic effect of nateglinide: angiotensin-converting enzyme inhibitors (ACEI).
Maltese: Dawn l-aġenti li jmiss jistgħu iżidu l-effett ipogliċemiku ta' nateglinide: impedituri ta' l-enzima talkonverżjoni ta' angiotensin (ACEI).
English: Keep this leaflet.
Maltese: L-ebda ħtiġijiet speċjali.
English: 1 film-coated tablet contains 60 mg nateglinide.
Maltese: Pillola 1 miksija b'rita fiha 60 mg nateglinide.
English: Take Trazec before meals (see section 3, “How to take Trazec”).
Maltese: Ħu Trazec qabel l-ikel (ara sezzjoni 3 “Kif għandek tieħu Trazec”).
English: In combination with metformin, which mainly affected fasting plasma glucose, the effect of nateglinide on HbA1c was additive compared to either agent alone.
Maltese: Ikkombinat ma' metformin, li jeffettwa l-izjed glucose fil-plażma waqt is-sawm, l-effett ta' nateglinide fuq HbA1c kien additiv meta mqabbel ma' kull aġent waħdu.
English: Rare: Hypersensitivity reactions such as rash, itching and urticaria.
Maltese: Disturbi fis-sistema immuni Rari: Sensittività eċċessiva bħal raxx, ħakk u urtikarja.
English: What Trazec contains
Maltese: Jekk tinsa tieħu Trazec
English: 1 film-coated tablet contains 120 mg nateglinide.
Maltese: Pillola 1 miksija b'rita fiha 120 mg nateglinide.
English: Trazec is contraindicated in patients with:
Maltese: Sustanzi mhux attivi:
English: Take special care with Trazec
Maltese: Trazec u l-Anzjani
English: It is used by people with type 2 diabetes.
Maltese: Tintuża minn nies b'dijabete tip 2.
English: However, there is a delay in the rate of absorption characterised by a decrease in Cmax and a delay in time to peak plasma concentration (tmax).
Maltese: Iżda, hemm dewmien fir-rata ta' assorbiment ikkaratterizzata minn tnaqqis tas- Cmax u dewmien fil-ħin biex tintlaħaq l-ogħla konċentrazzjoni fil-plażma (tmax).
English: The extent of serum protein binding is independent of drug concentration over the test range of 0.1-10 μg Trazec/ml.
Maltese: Kemm jeħel mal-proteini tas-serum jiddependi mill-konċentrazzjoni tal-mediċina fil medda ta' 0.1-10 µg Trazec/ml.
English: 1 film-coated tablet contains 180 mg nateglinide.
Maltese: Pillola 1 miksija b'rita fiha 180 mg nateglinide.
English: When a patient stabilised on any oral hypoglycaemic agent is exposed to stress such as fever, trauma, infection or surgery, a loss of glycaemic control may occur.
Maltese: Meta pazjent li jkun stabilizzat fuq aġenti ipogliċemiċi li jittieħdu mill-ħalq ikun esponut għal stress bħal deni, trawma, infezzjoni jew kirurġija, jista' jseħħ telf tal-kontroll gliċemiku.
English: Medicines, including Trazec, may also produce symptoms of low blood sugar.
Maltese: Mediċini, inkluż Trazec, jistgħu anke jikkawżaw sintomi ta' livell baxx ta' zokkor fiddemm.
English: Tel.: +48 22 550 8888
Maltese: Novartis Poland Sp. z o.o. Tel.: +48 22 550 8888
English: As with other antidiabetic agents, symptoms suggestive of hypoglycaemia have been observed after administration of nateglinide.
Maltese: Bħal fil-każ ta' aġenti antidiabetiċi oħra, sintomi li jindikaw ipogliċemija kienu osservati wara li ngħata nateglinide.
English: Plasma concentrations decline rapidly and the elimination half-life of nateglinide typically averaged 1.5 hours in all studies of Trazec in volunteers and type 2 diabetic patients.
Maltese: Ilkonċentrazzjonijiet fil-plażma malajr jonqsu u l-half-lifee tatt-tneħħija ta' nateglinide tipikament kellha medja ta' 1.5 sigħat fl-istudji kollha ta' Trazec f'voluntiera u f'pazjenti dijabetiċi tip 2.
English: In a clinical study in patients, Trazec was administered in increasing doses up to 720 mg a day for 7 days and was well tolerated.
Maltese: Fi studju kliniku, Trazec ingħata lill-pazjenti b'dożi li kienu miżjuda sa 720 mg kuljum għal 7 ijiem u kienu tollerati sew.
English: Nateglinide should be used with caution in patients with moderate hepatic impairment.
Maltese: Gruppi speċifiċi ta' pazjenti Nateglinide għandu jintuża b'attenzjoni f'pazjenti b'indeboliment epatiku moderat.
English: Hepatic impairment: The systemic availability and half-life of nateglinide in non-diabetic subjects with mild to moderate hepatic impairment did not differ to a clinically significant degree from those in
Maltese: Id-disponibilità sistemika u l-half-life ta' nateglinide f'pazjenti li mhumiex dijabetiċi b'indeboliment epatiku ħafif għal moderat ma kienx differenti b'mod klinikament sinifikanti minn dawk f'pazjenti b'saħħithom.
English: Trazec 180 mg film-coated tablets are red, ovaloid tablets with “NVR” marked on one side and “TSX”
Maltese: Trazec 180 mg pilloli miksijin b'rita huma ħomor, b'għamla ovali b'“NVR” immarkata fuq naħa u “TSX” fuq l-oħra.
English: Although there is a 49% decrease in Cmax of nateglinide in dialysis patients, the systemic availability and half-life in diabetic subjects with moderate to severe renal insufficiency (creatinine clearance 15-50 ml/min) was comparable between renal subjects requiring haemodialysis and healthy subjects.
Maltese: Għalkemm hemm tnaqqis ta' 49 % fis- Cmax ta' nateglinide f'pazjenti li jkunu fuq id-dijaliżi, iddisponibilità sistemika u l-half-life f'individwi dijabetiċi b' insuffiċjenza renali (tneħħija talkrejatinina 15-50 ml/min) kien jitqabbel bejn individwi renali li kellhomm bżonn id-dijaliżi tad-demm u individwi b'saħħithom.
English: Nateglinide is indicated for combination therapy with metformin in type 2 diabetic patients inadequately controlled despite a maximally tolerated dose of metformin alone.
Maltese: Nateglinide huwa indikat għal terapija kkombinata ma' metformin f'pazjenti b'dijabete tat-tip 2 li minkejja li jkunu qed jieħdu d-doża massima ta' metformin waħdu li jistgħu jifilħu ma jkunux kontrollati kif jixraq.
English: 60 mg pink, round, bevelled-edge tablets with “NVR” marked on one side and “TS” on the other.
Maltese: Pillola miksija b'rita Pilloli b'60 mg, roża, tondi, b'xifer imżerżaq b'“NVR” immarkat fuq naħa u “TS” fuq l-oħra.
English: Nateglinide is rapidly and almost completely (≥ 90%) absorbed from an oral solution.
Maltese: Nateglinide jiġi assorbit malajr u kważi għall-kollox (≥ 90 %) minn soluzzjoni orali.
English: Combination with metformin is associated with an increased risk of hypoglycaemia compared to
Maltese: Il-kombinazzjoni ma' metformin ġiet assoċjata ma' riskju akbar ta' ipogliċemija meta imqabbel ma' monoterapija.
English: It is best to take it right before a main meal but you can take it up to 30 minutes before.
Maltese: L-aħjar li tieħu Trazec qabel-ikla prinċipali iżda tista' tieħu d-doża sa 30 minuta qabel.
English: NAME OF THE MEDICINAL PRODUCT Trazec 180 mg tablets
Maltese: INFORMAZZJONI BIL-BRAILLE Trazec 180 mg
English: The active substance is nateglinide.
Maltese: X'Fih Trazec - Is-sustanza attiva hija nateglinide.
English: Particular caution is recommended when nateglinide is co-administered with other more potent inhibitors of CYP2C9, e.g. fluconazole or gemfibrozil, or in patients known to be poor metabolisers
Maltese: L-attenzjoni hija rakkomandata b'mod partikolari meta nateglinide jingħata flimkien ma' impedituri CYP2C9 aktar qawwija, eż. fluconazole u gemfibrizol, jew f'pazjenti magħrufa bħala metabolizzaturi dgħajfa ta' CYP2C9.
English: Tlf: +45 39 16 84 00
Maltese: Tel: +370 5 269 16 50
English: Common: Symptoms suggestive of hypoglycaemia.
Maltese: Disturbi fil-metaboliżmu u n-nutrizzjoni Komuni: Sintomi li jindikaw ipogliċemija.
English: Novartis Farma - Produtos Farmacêuticos, S.A. Tel: +351 21 000 8600
Maltese: Novartis Farmacéutica, S.A. Tel: +34 93 306 42 00
English: In type 2 diabetic patients, the insulinotropic response to a meal occurs within the first 15 minutes following an oral dose of nateglinide.
Maltese: F'pazjenti dijabetiċi tip 2, ir-reazzjoni insulinotropika għal ikla sseħħ fl-ewwel 15 minuti wara doża mill-ħalq ta' nateglinide.
English: Lactose monohydrate: 283 mg per tablet For a full list of excipients, see section 6.1.
Maltese: Lactose monohydrate: 283 mg għal kull pillola.
English: Preclinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to fertility and post-natal development.
Maltese: Tagħrif ta' qabel l-użu kliniku magħmula fuq studji konvenzjonali ta' sigurtà farmakoloġika, effett tossiku minn dożi ripetuti, effett tossiku fuq il-ġeni, riskju ta' kanċer, effett tossiku fuq il-fertilità u żvilupp ta' wara t-twelid, ma' juri l-ebda periklu speċjali għall-bnedmin.
English: Nateglinide is a rapid, short-acting oral insulin secretagogue.
Maltese: MINGĦAJR PERIKLU U EFFETTIV TAL-PRODOTT MEDIĊINALI
English: NAME OF THE MEDICINAL PRODUCT Trazec 120 mg tablets
Maltese: TAL-PRODOTT MEDIĊINALI TRAZEC 120 mg pilloli miksijin b'rita
English: B. CONDITIONS OF THE MARKETING AUTHORISATION
Maltese: .2 Inkompatibilitajiet
English: Thus, no dosage adjustment is required for digoxin, warfarin or other drugs that are CYP2C9 or CYP3A4 substrates upon coadministration with Trazec.
Maltese: Għalhekk, m'hemmx bżonn ta' tibdil fid-doża għal digoxin, warfarin u mediċini oħra li huma sottostrati ta' CYP 2C9 u CYP 3A4 meta jingħataw ma' Trazec.
English: Lactose monohydrate: 214 mg per tablet For a full list of excipients, see section 6.1.
Maltese: Lactose monohydrate: 214 mg għal kull pillola.
English: The systemic availability and half-life in dialysis-dependent diabetic patients was comparable with healthy subjects.
Maltese: Id-disponibilità sistemika u l-half-life f'pazjenti dijabetiċi li jiddependu middijaliżi kienet komparabbli ma' pazjenti b'saħħithom.
English: Important information about some of the ingredients of Trazec Trazec tablets contain lactose monohydrate.
Maltese: Tagħrif importanti dwar xi wħud mis-sustanzi ta' Trazec Il-pilloli Trazec fihom lactose monohydrate.
English: • Hypersensitivity to the active substance or to any of the excipients
Maltese: • Sensittività eċċessiva għas-sustanza attiva jew għal xi sustanzi mhux attivi.
English: NAME OF THE MEDICINAL PRODUCT TRAZEC 120 mg film-coated tablets
Maltese: Trazec 120 mg pilloli Nateglinide
English: Nateglinide should not be used in monotherapy.
Maltese: Fih lactose monohydrate.
English: NAME OF THE MEDICINAL PRODUCT TRAZEC 60 mg film-coated tablets
Maltese: TAL-PRODOTT MEDIĊINALI TRAZEC 60 mg pilloli miksijin b'rita
English: It is usually taken immediately (1 minute) before a meal but may be taken up to 30 minutes before meals.
Maltese: Ġeneralment jittieħed mill-ewwel (1 minuta) qabel ikla iżda jista' jittieħed sa 30 minuta qabel l-ikliet.
English: The side effects caused by Trazec are usually mild to moderate.
Maltese: Leffetti sekondarji ikkawżati minn Trazec huma ġeneralment ħfief għal moderati.
English: NAME OF THE MEDICINAL PRODUCT TRAZEC 180 mg film-coated tablets
Maltese: TAL-PRODOTT MEDIĊINALI TRAZEC 180 mg pilloli miksijin b'rita
English: NAME OF THE MEDICINAL PRODUCT Trazec 180 mg film-coated tablets
Maltese: Trazec 180 mg pilloli Nateglinide
English: Trazec and older people Trazec can be used by people over 65 years of age.
Maltese: Starllix jista' jintuża f' nies li għandhom iżjed minn 65 sena.
English: Approximately
Maltese: Nateglinide
English: Trazec 120 mg film-coated tablets are yellow, ovaloid tablets with “NVR” marked on one side and
Maltese: Trazec 120 mg pilloli miksijin b'rita huma sofor, b'għamla ovali b'“NVR” immarkata fuq naħa u “TSL” fuq l-oħra.
English: Novartis Poland Sp. z o.o.
Maltese: Novartis Pharma S.p.A.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 120 mg nateglinide.
Maltese: Kull pillola miksija b'rita fiha 120 mg nateglinide.
English: Nateglinide should be taken within 1 to 30 minutes before meals (usually breakfast, lunch and dinner).
Maltese: Nateglinide għandu jittieħed fi żmien 1 sa 30 minuta qabel l-ikel (normalment mal-kolazzjon, l-ikla ta' nofsinhar u l-ikla ta' filgħaxija).
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 60 mg nateglinide.
Maltese: Kull pillola miksija b'rita fiha 60 mg nateglinide.
English: 120 mg yellow, ovaloid tablets with “NVR” marked on one side and “TSL” on the other.
Maltese: Pillola miksija b'rita Pilloli b'120 mg sofor, b'għamla fl-ovali b'“NVR” immarkat fuq naħa u “TSL” fuq l-oħra.
English: These symptoms included sweating, trembling, dizziness, increased appetite, palpitations, nausea, fatigue, and weakness.
Maltese: Dawn is-sintomi kienu jinkludu għaraq, rogħda, sturdament, żieda fl-aptit, palpitazzjonijiet, tqallih, għeja, u dgħjufija.
English: when taken before a meal, restores early or first phase insulin secretion, which is lost in patients with type 2 diabetes, resulting in a reduction in post-meal glucose and HbA1c.
Maltese: Nateglinide, meta jittieħed qabel ikla, ireġġa' lura l-ħila ta' sekrezzjoni ta'insulina minn kmieni jew mill-ewwel fażi, li tkun intilfet f'pazjenti b'dijabete tip 2, li tirriżulta fit-tnaqqis ta' glucose ta' wara likel u tnaqqis ta' HbA1c.
English: Invented name Strength Pharmaceutical form Route of administration Packaging
Maltese: Qawwa Għamla farmaċewtika
English: Lot {number}
Maltese: Lot {numru}
English: See section 4.7.
Maltese: Ara sezzjoni 4.7.
English: Date of last renewal: 08/09/2015
Maltese: Data tal-aħħar tiġdid: 08/09/2015
English: ATCvet code: QM01AC06.
Maltese: QM01AC06
English: Oral suspension.
Maltese: Suspensjoni orali.
English: 4941 SJ Raamsdonksveer THE NETHERLANDS
Maltese: 4941 SJ Raamsdonksveer L-OLANDA
English: Manufacturer for the batch release: Produlab Pharma B.V.
Maltese: Manifattur li jħalli l-konsenja tmur fis-suq: Produlab Pharma B.V.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Maltese: Il-frekwenza ta' effetti mhux mixtieqa hija definita skont din il-konvenzjoni: - komuni ħafna (aktar minn wieħed f'10 annimali li juru effetti mhux mixtieqa matul il-perjodu ta' kura waħda) - komuni (aktar minn wieħed iżda inqas minn 10 annimali f'100 annimal) - mhux komuni (aktar minn wieħed iżda inqas minn10 annimali f'1,000 annimal) - rari (aktar minn wieħed iżda inqas minn10 annimali f'10,000 annimal) - rari ħafna (inqas minn annimal wieħed f'10,000 annimal, inklużi rapporti iżolati).
English: Bottle of 10, 25, 50, 125 or 180 ml.
Maltese: Flixkun ta' 10, 25, 50, 125 jew 180 ml.
English: Approximately 97% of meloxicam is bound to plasma proteins.
Maltese: Madwar 97% ta' meloxicam jeħel mal-proteini tal-plażma.
English: Response to long-term therapy should be monitored at regular intervals by a veterinary surgeon.
Maltese: Ir-rispons għat-terapija fit-tul għandu jkun immonitorjat f'intervalli regolari minn kirurgu veterinarju.
English: Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites.
Maltese: Ħames metaboliti prinċipali ġew identifikati. Meloxicam huwa metabolizzat għal alkoħol, derivattiv ta' aċidu u għal diversi metaboliti polari.
English: Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects.
Maltese: Meloxicam hu mediċina mhux sterojdi kontra l-infjammazzjoni (NSAID) tal-klassi oxicam li taġixxi bl-inibizzjoni tas-sintesi ta' prostaglandin, u b'hekk teżerċita effetti anti-infjammatorji, analġesiċi, kontra t-tnixxija u antipiretiċi.
English: 5.1 Pharmacodynamic properties
Maltese: 5.1 Kwalitajiet Farmakodinamikuċi
English: Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects.
Maltese: NSAIDs oħrajn, dijuretiċi, antikoagulanti, antibijotiċi aminoglikosidi u sustanzi oħra li jeħlu ħafna mal-proteini, jistgħu jikkompetu għat-twaħħil u b'hekk iwasslu għal effetti tossiċi.
English: A clinical response is normally seen within 7 days.
Maltese: Rispons kliniku normalment jidher fi żmien 7 ijiem.
English: Polyethylene bottle containing 10 ml, 25 ml, 50 ml, 125 ml or 180 ml with a tamper proof child resistant closure and a polypropylene measuring syringe.
Maltese: Flixkun tal-polyethylene li fih 10 ml, 25 ml, 50 ml, 125 ml jew 180 ml b'qattara tal-polyethylene u b'tapp li jirreżisti l-ftuħ mit-tfal żgħar.
English: In very rare cases haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported.
Maltese: F'każijiet rari ħafna ġew irrappurtati dijarea emorraġika, ematemesi, ulċerazzjoni gastrointestinali u livell għoli ta' enzimi tal-fwied.
English: Tel: +385 1 33 88 602 info@genera.hr
Maltese: HR-10436 Rakov Potok Tel: +385 1 33 88 602 info@genera.hr
English: Date of first authorisation: 19/11/2010.
Maltese: DATA TAL-EWWEL AWTORIZZAZZJONI/TIĠDID TAL-AWTORIZZAZZJONI Data tal-ewwel awtorizzazzjoni: 19/11/2010.
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Maltese: DATA TA' META ĠIET RIVEDUTA DIN IL-KITBA Informazzjoni dettaljata dwar dan il-prodott mediku veterinarju tinstab fuq il-websajt tal-Aġenzija Ewropea għall-Mediċini (http://www.ema.europa.eu/).
English: Pharmacotherapeutic group: Musculo-skeletal system,antiinflammatory and antirheumatic products, non-steroids.
Maltese: Prodotti tas-sistema muskolo-skeletali anti-infjammatorji u anti rewmatiċi, mhux sterojdi
English: Excipient:
Maltese: EXP.
English: Cats
Maltese: Biss.
English: Produlab Pharma B.V. Forellenweg 16
Maltese: Produlab Pharma B.V.
English: 3421 TV Oudewater THE NETHERLANDS
Maltese: 3421 TV Oudewater The Netherlands Tel.